Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation

被引：24

作者：

Baron, F ^{[1
]}

Beguin, Y ^{[1
]}

机构：

[1] Univ Liege, Dept Med, Div Hematol, Liege, Belgium

来源：

TRANSFUSION | 2000年 / 40卷 / 04期

关键词：

D O I：

10.1046/j.1537-2995.2000.40040468.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：468 / 476

页数：9

共 90 条

[21]

DELAIN M, 1994, LEUKEMIA, V8, P642

[22] EFFECT OF T-CELL DEPLETION AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS ON ENGRAFTMENT, RELAPSE, AND DISEASE-FREE SURVIVAL IN UNRELATED MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA [J].

DROBYSKI, WR ;

ASH, RC ;

CASPER, JT ;

MCAULIFFE, T ;

HOROWITZ, MM ;

LAWTON, C ;

KEEVER, C ;

BAXTERLOWE, LA ;

CAMITTA, B ;

GARBRECHT, F ;

PIETRYGA, D ;

HANSEN, R ;

CHITAMBAR, CR ;

ANDERSON, T ;

FLOMENBERG, N .

BLOOD, 1994, 83 (07) :1980-1987

[23]

DROBYSKI WR, 1993, BLOOD, V82, P2310

[24] RECOGNITION OF CLONOGENIC LEUKEMIC-CELLS, REMISSION BONE-MARROW AND HLA-IDENTICAL DONOR BONE-MARROW BY CD8+ OR CD4+ MINOR HISTOCOMPATIBILITY ANTIGEN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES [J].

FABER, LM ;

VANDERHOEVEN, J ;

GOULMY, E ;

OTTER, ALH ;

VANLUXEMBURGHEIJS, SAP ;

WILLEMZE, R ;

FALKENBURG, JHF .

JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (02) :877-883

[25] Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes [J].

Falkenburg, JHF ;

Wafelman, AR ;

Joosten, P ;

Smit, WM ;

van Bergen, CAM ;

Bongaerts, R ;

Lurvink, E ;

van der Hoorn, M ;

Kluck, P ;

Landegent, JE ;

Kluin-Nelemans, HC ;

Fibbe, WE ;

Willemze, R .

BLOOD, 1999, 94 (04) :1201-1208

[26] Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions [J].

Fuchs, EJ ;

Seber, A ;

Altomonte, V ;

Braine, HG ;

Humphrey, RL ;

Jones, RJ ;

Noga, SJ ;

Schepers, K ;

Wright, SK ;

Vogelsang, GB .

BONE MARROW TRANSPLANTATION, 1998, 22 (03) :303-305

[27] CD8-DEPLETED DONOR LYMPHOCYTE INFUSION AS TREATMENT FOR RELAPSED CHRONIC MYELOGENOUS LEUKEMIA AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].

GIRALT, S ;

HESTER, J ;

HUH, Y ;

HIRSCHGINSBERG, C ;

RONDON, G ;

SEONG, D ;

LEE, M ;

GAJEWSKI, J ;

VANBESIEN, K ;

KHOURI, I ;

MEHRA, R ;

PRZEPIORKA, D ;

KORBLING, M ;

TALPAZ, M ;

KANTARJIAN, H ;

FISCHER, H ;

DEISSEROTH, A ;

CHAMPLIN, R .

BLOOD, 1995, 86 (11) :4337-4343

[28]

GIRT S, 1995, BLOOD, V86, P4337

[29] Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia [J].

Glass, B ;

Uharek, L ;

Zeis, M ;

Loeffler, H ;

MuellerRuchholtz, W ;

Gassmann, W .

BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (02) :412-420

[30] BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE - INCREASED RISK FOR RELAPSE ASSOCIATED WITH T-CELL DEPLETION [J].

GOLDMAN, JM ;

GALE, RP ;

HOROWITZ, MM ;

BIGGS, JC ;

CHAMPLIN, RE ;

GLUCKMAN, E ;

HOFFMANN, RG ;

JACOBSEN, SJ ;

MARMONT, AM ;

MCGLAVE, PB ;

MESSNER, HA ;

RIMM, AA ;

ROZMAN, C ;

SPECK, B ;

TURA, S ;

WEINER, RS ;

BORTIN, MM .

ANNALS OF INTERNAL MEDICINE, 1988, 108 (06) :806-814

← 1 2 3 4 5 6 7 8 9 →